Jasper Therapeutics (NASDAQ:JSPR) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Jasper Therapeutics (NASDAQ:JSPR) announced its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17, FiscalAI reports.

Jasper Therapeutics Price Performance

Shares of JSPR stock traded down $0.07 during mid-day trading on Friday, hitting $0.79. 567,510 shares of the stock traded hands, compared to its average volume of 2,265,872. The stock has a market cap of $22.12 million, a P/E ratio of -0.24 and a beta of 3.02. The stock’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.91. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.14.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JSPR shares. Piper Sandler initiated coverage on Jasper Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $2.00 target price for the company. Wall Street Zen downgraded Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Jasper Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.17.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quadrature Capital Ltd purchased a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $123,000. Millennium Management LLC grew its holdings in Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after purchasing an additional 708,844 shares during the last quarter. Engineers Gate Manager LP purchased a new position in Jasper Therapeutics in the fourth quarter worth $26,000. Boothbay Fund Management LLC increased its position in shares of Jasper Therapeutics by 79.4% during the fourth quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock worth $1,453,000 after purchasing an additional 351,312 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter worth $256,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.